Common chronic diseases, such as hypertension and diabetes, are referred to as “silent epidemics.” This term is relevant to chronic kidney disease (CKD), which manifests without overt symptoms in most patients. Timely identification through laboratory criteria is necessary to enable patients, providers, and health systems to triage, treat, and prevent the progression of CKD.1 Although up to 1 in 7 Americans has CKD, only 10% of patients with CKD stage 3 and 40% with CKD stage 4 are aware of their diagnosis.